LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $4.99 per share. The engine maker posted revenue of $8.64 billion in the period, also exceeding Street ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...